How we change lives
ABOUT
Investing in Healthcare
Investing in the resilient Health Care sector
Horizon 3 is building a portfolio we expect to deliver an IRR of 20% per annum over a 5 year timeframe. *
Investing in healthcare products that have global growth potential – medical devices, drugs, digital health and diagnostics.
* returns are not guaranteed
Backing companies with runs on the board
Growth stage healthcare companies with runs on the board – typically already have achieved clinical validation and are revenue generating.
World Class CIO
Led by one of Australia’s Leading Healthcare investors, CIO Matt McNamara, Molecular biologist
Previous funds delivered top quartile returns and backed 3 unicorns.
Horizon 3 is Matt’s 5th fund over the past 20+ years.
Investment Portfolio
We invest in the long term by contributing capital, business excellence, deep commercialisation partnerships and unparalleled health science expertise.
From bright thinking to better health outcomes, and ultimately returns for our investors.
INVEST
PORTFOLIO
Cardiac Dimensions
Canary Health
EBR Systems
Avecho
Neuren
OUR TEAM
We are a powerful team made up of seasoned entrepreneurs, life science specialists and experienced investors who are experts at finding great ideas in which to invest. Our efforts are focused on selecting talented life sciences teams and companies with huge potential.
Matt McNamara
Chief Investment Officer & Board Director
Bev Thomas
Senior Investment Professional & Investment Committee Member
Paul Field
Life Sciences Business Development Exec & Investment Committee Member
Dr Qibing Mei
Pharmacologist & Investment Committee Member
Scott Power
Investment Analyst & Investment Committee Member
Assoc Prof Tam Nguyen
Non-Executive Director and Deputy Director of Research
Mike Sullivan
Banking and Capital Markets Executive & Board Executive Chairman
Jian Sun
Entrepreneur and founder of HK Biotechnology & Board Director
Robin Chambers AO
Corporate Lawyer and Advisor & Board Director
Glenn Cross
Senior Corporate Advisor & Board Director
Claire Newstead-Sinclair
Company Secretary
DISCLAIMER: Investing in venture capital funds carries significant risks, including potential loss of capital. While we target an IRR of 20% per annum over a 5-year timeframe, past performance is not indicative of future results, and returns may vary depending on market conditions and investment performance. The past performance of our CIO in previous funds, while operating under similar mandates, does not guarantee future results for H3 Healthcare. It’s important to note that these prior investments were managed by different teams and under separate entities. While we aim to apply similar strategies, the current fund operates under unique market conditions and with a distinct team structure.
